The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Targeting I2PP2A by FTY720: A novel, mechanism-based treatment strategy for patients with advanced and previously treated non-small cell lung cancer (NSCLC).
G. R. Simon
No relevant relationships to disclose
S. Saddoughi
No relevant relationships to disclose
A. Mukhopadhyay
No relevant relationships to disclose
Y. Peterson
No relevant relationships to disclose
C. E. Senkal
No relevant relationships to disclose
J. Oaks
No relevant relationships to disclose
D. Perrotti
No relevant relationships to disclose
Y. Hannun
No relevant relationships to disclose
B. Ogretmen
No relevant relationships to disclose